Managing Aggressive Disease After IO and TKI in Advanced Renal Cell Carcinoma

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein introduces a patient with high disease burden who progresses within 8 months of frontline immunotherapy plus VEGF receptor targeted therapy, highlighting a more aggressive disease course. He emphasizes that early progression and limited depth of response raise concern for more refractory disease biology.

Dr. Singer discusses how this clinical scenario influences second-line decision-making, noting that shorter duration of response is often associated with more aggressive disease. He emphasizes the need for a more intensive treatment approach, typically favoring sequential VEGF receptor targeted therapies. He explains that despite prior exposure, switching to an alternative TKI can still provide clinical benefit due to differences in kinase inhibition profiles. In this setting, he often selects a more potent regimen, particularly when there is concern about rapid progression. The discussion highlights the importance of tailoring treatment intensity to disease aggressiveness in advanced renal cell carcinoma.